All Oncology News

Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.

Ruxolitinib induced clinically meaningful overall survival improvements by decreasing non-relapse mortality rates in patients with acute graft-vs-host-disease.

First-line treatment with itolizumab produced rapid, durable responses and favorable safety in patients with acute graft-vs-host disease.

Timing of severe symptom onset is the only distinct difference between late and classic acute graft-vs-host disease, and long-term outcomes were similar between the two types of disease.

Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.

Bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 90-day complete response rate of 92% in patients with relapsed/refractory mantle cell lymphoma.

Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology 2023 Junior Faculty Scholar Award in basic/translational research.

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.

The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.

The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.

The dual CD19- and CD20-directed, freshly administered CAR T-cell therapy zamtocabtagene autoleucel elicited a high response rate with deepening responses over time in patients with relapsed/refractory diffuse large B-cell lymphoma.

An independent data monitoring committee has recommended that a phase 3 trial evaluating uproleselan plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia should continue to the planned overall survival event trigger.

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Toripalimab plus gemcitabine and cisplatin demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone as frontline therapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

The FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment.

Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.

Cedars-Sinai investigators verify that rates are trending up for both sexes; younger women and Black women see steepest increase.

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

François-Clément Bidard, MD, PhD, discusses how elacestrant fits into the treatment paradigm for postmenopausal patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

The FDA has issued a refusal to file letter for a new drug application seeking the approval of HyBryte, Soligenix’s synthetic hypericin, for use in patients with early-stage cutaneous T-cell lymphoma.

Treatment with brexucabtagene autoleucel in the standard-of-care relapsed/refractory mantle cell lymphoma setting provided an efficacy and safety profile consistent with data reported in the phase 2 ZUMA-2 trial.